Squarepoint’s Cardiff Oncology CRDF Stock Holding History
Bought
Maintained
Sold
Other funds holding CRDF
LCM
P
Squarepoint's CRDF Position: Q2 2026 in Review
Squarepoint increased its Cardiff Oncology (CRDF) stake by 265% in Q2 2026, buying an estimated $111K and bringing the position to 96,090 shares worth $125K. The position accounts for ﹤0.01% of the portfolio, ranked #4167.
Squarepoint first reported a position in CRDF in Q4 2021 and has held it in 6 quarters since. The position peaked at $402K in Q1 2025. 105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.
- Squarepoint held 96,090 shares of Cardiff Oncology worth $125K as of Q2 2026.
- Squarepoint bought 69,734 Cardiff Oncology shares in Q2 2026, an estimated $111K.
- Cardiff Oncology made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #4167 holding.
- Squarepoint first reported a position in Cardiff Oncology in Q4 2021 and has held it in 6 quarters since.
- Squarepoint's Cardiff Oncology position peaked at $402K in Q1 2025.
- 105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.
Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.